Last Price Today's Change   Day's Range   Trading Volume
0.28   -0.01 (3.45%)  0.27 - 0.295  20,358,963


Avg Volume (4 weeks):25,092,231
4 Weeks Range:0.212 - 0.315
4 Weeks Price Volatility (%):
52 Weeks Range:0.13 - 0.625
52 Weeks Price Volatility (%):
Average Price Target:-


No recent Headlines for this stock.

Business Background

Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.

  Be the first to like this.

I3 Messenger
Individual or Group chat with anyone on I3investor

640  881  615  1490 

Top 10 Active Counters
 TMS 0.049+0.01 
 4DS 0.031+0.002 
 SYA 0.26-0.015 
 PLS 3.12-0.05 
 AZL 0.094-0.006 
 LKE 1.265-0.075 
 1MC 0.026-0.002 
 88E 0.011+0.001 
 CVN 0.165-0.035 
 DRE 0.105+0.017